Follistatin Antibody (85920) [Unconjugated]

Recombinant Human Follistatin protein was serially diluted 2-fold and captured by Mouse Anti-Human Follistatin Monoclonal Antibody (Catalog # MAB6691) coated on a Clear Polystyrene Microplate (Catalog # DY990). Mouse Anti-Human Follistatin Monoclonal Antibody (Catalog # MAB6692) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998) followed by Substrate Solution (Catalog # DY999) and stopping the enzymatic reaction with Stop Solution (Catalog # DY994).

• Reactivity: Hu
• Applications: ELISA
• Clone: 85920
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

Follistatin Antibody (85920) [Unconjugated] Summary

• Immunogen: S. frugiperda insect ovarian cell line Sf 21-derived recombinant human Follistatin
  Gly30-Asp329
  Accession # P19883
• Specificity: Detects human Follistatin in direct ELISAs.
• Source: N/A
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from ascites

Applications/Dilutions

• Dilutions:
  • ELISA

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Follistatin Antibody (85920) [Unconjugated]

• follistatin isoform FST317
• Follistatin
• FS
• FSActivin-binding protein
• FST

Background

Follistatin (FST) is a secreted glycoprotein that was first identified as a follicle-stimulating hormone inhibiting substance in ovarian follicular fluid (1, 2). Human Follistatin cDNA encodes a 344 amino acid (aa) protein with a 29 aa signal sequence, an N-terminal atypical TGF binding domain, three Follistatin domains that contain EGF-like and kazal-like motifs, and a highly acidic C-terminal tail. The first Follistatin domain (FS1) contains a heparin binding site, while FS1 and FS2 are most critical for activin binding and neutralization (3, 4). In addition to activin, Follistatin regulates bioavailability of many non-TGF-beta members of the TGF-beta superfamily, such as BMP6, BMP7 and myostatin (5). It also regulates hematopoietic stem cell adhesion to fibronectin via FS2, and binds angiogenin via FS2 and FS3 (6, 7). Some Follistatin binding partners will also bind Follistatin-like proteins such as FSL-3 (3, 5, 6). Of three Follistatin isoforms, the full-length mature Follistatin (FST315) is the most abundant and the sole form in plasma, but has lower binding affinity for both activins and heparins than alternative isoforms (5, 8, 9). The acidic tail is missing in the splice variant FST288 which shows the highest affinity for activins, while a partial tail exists in the proteolytically produced FST303, which shows intermediate activin affinity (5, 8, 9). FST315 shares 98% aa identity with mouse, rat, equine and ovine FST, 99% with porcine and 97% with bovine FST. Genetic deletion of Follistatin in mice, or expression of only the FST288 form, is perinatally lethal due to defects of lung, skin and musculoskeletal system (10). Expression of only the FST315 isoform allows survival, with defects in vascularization and female fertility (10).

1. Shimasaki, S. et al. (1988) Proc. Natl. Acad. Sci. USA 85:4218. 
2. Thompson, T.B. et al. (2005) Dev. Cell 9:535. 
3. Sidis, Y. et al. (2005) Endocrinology 146:130. 
4. Keutmann, H.T. et al. (2004) Mol. Endocrinol. 18:228. 
5. Sidis, Y. et al. (2006) Endocrinology 147:3586. 
6. Maguer-Satta, V. et al. (2006) Exp. Cell Res. 312:434.
7. Gao, X. et al. (2007) FEBS Lett. 581:5505.
8. Lerch, T.F. et al. (2007) J. Biol. Chem. 282:15930.
9. Schneyer, A.L. et al. (2004) J. Clin. Endocrinol. Metab. 89:5067.
10. Lin, S-Y. et al. (2008) Mol. Endocrinol. 22:415.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • P19883()